2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 295

Uveitis In The Nordic Juvenile Idiopathic Arthritis Cohort; High Incidence, Frequent Complications, and Gender Associated Risk Factors
Abstract Number: 679

Validation Of a Novel Radiographic Scoring System For Calcinosis Affecting The Hands Of Patients With Systemic Sclerosis
Abstract Number: 2239

Validation Of a Patient Reported Experience Measure In Patients With Rheumatoid Arthritis
Abstract Number: 1128

Validation Of a Rapid, Quantitative Method Of Magnetic Resonance Imaging-Detected Osteoarthritis-Related Bone Marrow Lesions In The Patellofemoral Joint
Abstract Number: 2501

Validation Of Gene Expression Biomarkers Of Psoriatic Arthritis
Abstract Number: 1383

Validation Of Popliteal Lymph Node Phenotype and Bin Expansion As Biomarkers Of Rheumatoid Arthritis Knee Flare
Abstract Number: 1550

Validation Of The Ankylosing Spondylitis Disease Activity Score and Effectiveness Of Infliximab In The Treatment Of Ankylosing Spondylitis Over 4 Years: The Canadian Experience
Abstract Number: 1935

Validation Of The Cutaneous Dermatomyositis Disease Area and Severity Index: Characterizing Severity and Assessing Responsiveness To Clinical Change
Abstract Number: 2871

Validation Of The FLARE Self-Report Questionnaire For Assessing FLARE Out Of The Clinical Visit In Rheumatoid Arthritis
Abstract Number: 1980

Validation Of The Fox-Walk Test In People With Rheumatoid Arthritis
Abstract Number: 1926

Validation Of The Hospital For Special Surgery Knee Questionnaire: Convergent Validity, Responsiveness and Sensitivity To Change
Abstract Number: 1811

Validation Of The ICD-CM-9 Code For Systemic Sclerosis Using Updated ACR/EULAR Classification Criteria
Abstract Number: 1910

Validation Of The Mayo Hip Questionnaire: Validity and Sensitivity To Change
Abstract Number: 753

Validation Of The New Histopathological Classification Of ANCA Glomerulonephritis and Its Association With Renal Outcomes In a Paediatric Population
Abstract Number: 2542

Validation Of The Revised Selena Flare Index In Systemic Lupus Erythematosus

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].